SENS Profile
Senseonics Holdings, Inc. is a prominent medical technology company specializing in the development and commercialization of advanced continuous glucose monitoring (CGM) systems. The company focuses on providing innovative solutions for people with diabetes, operating in markets across the United States, Europe, the Middle East, and Africa. Senseonics is particularly known for its long-term implantable CGM systems, which offer a revolutionary approach to glucose monitoring.
The company’s flagship products, Eversense and Eversense XL, represent significant advancements in CGM technology. These implantable systems are designed to provide continuous glucose monitoring through a sensor that is placed under the skin. The sensor works in conjunction with a removable and rechargeable smart transmitter, which communicates with a mobile app to deliver real-time glucose data to users. This system allows for up to six months of continuous glucose monitoring without the need for frequent sensor replacements, enhancing convenience and accuracy in diabetes management.
Senseonics supports its products through a network of distributors and strategic fulfillment partners, ensuring broad accessibility and effective support for both healthcare providers and patients. The company also collaborates with healthcare organizations, such as the University Hospitals Accountable Care Organization, to further its reach and improve patient care. This collaboration helps integrate Senseonics' technology into broader diabetes care programs, promoting better management of the condition.
Founded in 1996 and headquartered in Germantown, Maryland, Senseonics Holdings, Inc. has established itself as a leader in the field of CGM systems. The company’s commitment to innovation and its focus on providing long-term glucose monitoring solutions underscore its role in advancing diabetes care and improving the quality of life for individuals with diabetes.
|
